zika
viru
zikv
member
flaviviru
genu
flavivirida
famili
emerg
mosquitoborn
pathogen
zikv
close
relat
flavivirus
dengu
denv
yellow
fever
yfv
west
nile
wnv
japanes
enceph
jev
tickborn
enceph
tbev
virus
sinc
zikv
first
identifi
among
rhesu
macaqu
zika
forest
uganda
new
variant
becom
increasingli
preval
adapt
human
popul
recent
outbreak
spread
across
america
caribbean
southeast
asia
peak
outbreak
sever
incid
import
zikv
infect
identifi
mainland
china
contrast
previou
epidem
recent
zikv
outbreak
associ
sever
neurolog
complic
syndrom
adult
microcephali
fetus
newborn
current
zikvspecif
therapeut
vaccin
avail
high
preval
vector
continu
evolut
viral
speci
rais
seriou
concern
public
health
zikvrel
diseas
control
surfac
envelop
glycoprotein
e
flavivirus
mediat
entri
present
potenti
target
neutral
antibodi
larg
number
etarget
monoclon
antibodi
mab
identifi
potent
neutral
activ
epitop
specif
previous
isol
character
panel
etarget
mab
plasma
memori
b
cell
sequenti
blood
sampl
zikvinfect
convalesc
patient
acquir
zikv
infect
venezuela
outbreak
return
china
among
mab
show
highest
neutral
potenc
zikv
without
detect
reactiv
denv
also
demonstr
remark
prophylact
therapeut
activ
lethal
challeng
mous
model
zikv
infect
microcephali
crystal
structur
cryoem
analysi
reveal
recogn
later
ridg
e
diii
block
infect
inhibit
membran
fusion
cellular
attach
sinc
may
serv
promis
candid
antibodybas
intervent
ontogeni
could
provid
insight
protect
antibodi
respons
zikv
infect
human
inform
ration
vaccin
design
furthermor
divers
vaccin
candid
demonstr
abil
protect
zikv
challeng
mice
nonhuman
primat
nhp
evalu
preclin
clinic
studi
therefor
imper
investig
dynam
characterist
antibodi
repertoir
zikv
infect
longitudin
shed
light
molecular
requir
necessari
develop
effect
zikv
vaccin
studi
appli
longread
nextgener
sequenc
ng
unbias
repertoir
captur
method
longitudin
analyz
b
cell
repertoir
earli
acut
phase
late
convalesc
phase
obtain
ten
million
antibodi
sequenc
total
seven
sequenti
time
point
includ
day
day
month
month
month
month
month
onset
symptom
first
perform
ng
analysi
antibodi
repertoir
focu
germlin
gene
usag
loop
length
degre
somat
hypermut
shm
data
reveal
antibodi
repertoir
profil
zikv
infect
consist
divers
germlin
gene
usag
combin
steadi
distribut
loop
contrast
chronic
infect
often
exhibit
unusu
repertoir
profil
characterist
high
degre
shm
skew
germlin
gene
usag
long
loop
emerg
germlinelik
antibodi
observ
day
onset
symptom
trace
antibodi
lineag
within
ngsderiv
repertoir
investig
matur
pathway
result
show
gener
rel
low
titer
along
germlinelik
antibodi
day
somat
variant
synthes
function
character
vitro
vivo
germlinelik
heavi
chain
variant
demonstr
strong
neutral
activ
protect
lethal
zikv
challeng
mous
model
note
two
substitut
occur
posit
chain
found
critic
function
matur
summari
repertoir
lineag
analys
elucid
matur
pathway
potent
neutral
antibodi
suggest
germlinelik
antibodi
may
play
import
role
protect
immun
zikv
infect
blood
sampl
donat
chines
zikv
convalesc
male
patient
travel
venezuela
southern
metropolitan
citi
guangzhou
china
februari
hospit
followup
visit
total
sequenti
blood
sampl
collect
day
day
month
month
month
month
month
onset
symptom
sampl
separ
plasma
peripher
blood
mononuclear
cell
pbmc
centrifug
ficollhypaqu
gradient
ge
healthcar
pbmc
cryopreserv
freez
media
store
liquid
nitrogen
analysi
antibodi
repertoir
sequenc
improv
version
rapid
amplif
cdna
polymeras
chain
reaction
pcr
protocol
sampl
prepar
report
recent
studi
total
rna
extract
million
pbmc
ml
water
rneasi
mini
kit
qiagen
valencia
ca
unbias
repertoir
analysi
perform
smarter
race
cdna
amplif
kit
clontech
mountain
view
ca
genespecif
lineag
analysi
revers
transcript
rt
perform
superscript
iii
life
technolog
oligo
dt
case
cdna
purifi
elut
elut
buffer
nucleospin
pcr
cleanup
kit
clontech
immunoglobulin
pcr
set
platinum
taq
highfidel
dna
polymeras
life
technolog
carlsbad
ca
total
volum
cdna
templat
primer
genespecif
forward
primer
revers
primer
facilit
deep
sequenc
ion
genestudio
system
forward
primer
genespecif
contain
adaptor
revers
primer
contain
adaptor
ion
xpresstm
barcod
life
technolog
differenti
librari
variou
time
point
total
cycl
pcr
perform
pcr
product
bp
pcr
bp
genespecif
pcr
gel
purifi
qiagen
valencia
ca
degener
primer
saggtgcagctggtgcagtctgg
use
forward
genespecif
primer
cover
potenti
variat
transcript
antibodi
ng
adapt
ion
genestudio
system
briefli
antibodi
heavi
light
chain
librari
quantit
use
fluoromet
dsdna
hs
assay
kit
equal
amount
heavi
chain
librari
variou
time
point
mix
load
onto
ion
chip
increas
sequenc
depth
elimin
runtorun
variat
chain
librari
time
point
mix
ratio
prior
librari
pool
chip
load
templat
prepar
ion
chip
load
perform
ion
chef
system
use
ion
ext
kit
follow
sequenc
default
set
raw
data
process
without
trim
base
call
extend
read
length
human
antibodyom
pipelin
version
modifi
improv
data
accuraci
comput
effici
new
antibodyom
pipelin
use
process
annot
antibodi
ng
data
repertoir
profil
lineag
trace
distribut
germlin
gene
germlin
diverg
degre
shm
loop
length
deriv
antibodi
ng
data
gener
repertoir
profil
twodimension
divergenceident
plot
construct
visual
zikvspecif
antibodi
lineag
context
antibodi
repertoir
ident
use
cutoff
identifi
sequenc
evolutionarili
relat
refer
antibodi
shown
magenta
dot
plot
hierarch
cluster
method
use
divid
somat
variant
group
base
overal
ident
cutoff
previous
describ
addit
domin
sequenc
consensu
manual
select
sequenc
use
group
repres
antibodi
synthesi
function
character
initi
isol
pbmc
previous
report
synthet
variabl
region
gene
antibodi
heavi
chain
vh
light
chain
vkl
analyz
use
imgtvquest
server
http
wwwimgtorgimgtindexvquestphp
clone
backbon
antibodi
express
vector
contain
constant
region
human
previous
describ
produc
fulllength
human
mab
recombin
clone
pair
complementari
chain
wildtyp
wt
heavi
light
chain
express
plasmid
transient
cotransfect
hek
cell
product
fulllength
human
igg
purifi
supernat
affin
chromatographi
use
protein
agaros
thermo
scientif
igg
concentr
determin
use
bca
protein
assay
kit
thermo
scientif
includ
previous
report
merscovspecif
mab
compar
analysi
gene
either
e
protein
e
diii
protein
residu
zikv
without
tag
clone
vector
novagen
express
iptginduct
ril
bacteri
cell
isol
inclus
bodi
solubil
refold
report
enzymelink
immunosorb
assay
elisa
e
protein
e
diii
protein
captur
separ
onto
elisa
plate
overnight
test
mab
serial
dilut
appli
zikv
e
e
diii
proteincaptur
elisa
plate
bind
activ
detect
use
igg
label
hrp
tmb
substrat
zikv
zikv
virus
grown
aed
albopictu
cell
titrat
vero
cell
use
neutral
assay
serial
dilut
mab
mix
viru
h
appli
vero
cell
cultur
plate
h
infect
antibodyviru
mixtur
aspir
vero
cell
wash
pb
overlaid
dmem
contain
heatinactiv
fb
seaplaqu
agaros
lonza
day
plaqu
stain
crystal
violet
count
manual
mice
defici
interferon
ifn
receptor
mice
kindli
provid
institut
pasteur
shanghai
chines
academi
scienc
ip
mice
bred
maintain
pathogenfre
anim
facil
group
sexmatch
mice
use
anim
studi
prophylaxi
assay
test
mab
isotyp
control
administ
via
ip
rout
follow
day
anim
challeng
pfu
zikv
strain
via
ip
inject
surviv
monitor
day
post
challeng
day
challeng
whole
blood
collect
anim
zikv
viral
load
measur
whole
blood
collect
rnase
free
eppendorf
tube
contain
lysi
buffer
qiagen
store
use
total
rna
extract
use
rneasi
mini
kit
qiagen
reversetranscrib
cdna
use
iscript
cdna
synthesi
kit
biorad
viral
rna
copi
quantifi
taqman
qpcr
amplif
zikv
envelop
gene
measur
express
viral
rna
copi
per
millimet
calcul
standard
curv
sequenc
primer
probe
follow
zikvf
ccgctgcccaacacaag
zikvr
ccactaacgttcttttgcagacat
zikvprob
agcctaccttgacaagcartcagacactcaa
multipl
sequenc
align
msa
calcul
use
bioedit
clustalw
crystal
structur
zikv
e
fab
complex
determin
analyz
identifi
hotspot
residu
critic
lineag
develop
intermolecular
interact
shown
figur
use
maxim
cutoff
distanc
hydrogen
bond
illustr
structur
model
prepar
use
pymol
molecular
graphic
system
data
analyz
use
softwar
graphpad
halfmaxim
effect
concentr
calcul
use
doserespons
stimul
model
valu
mab
calcul
use
doserespons
inhibit
model
experi
involv
mice
four
anim
includ
assess
group
ensur
equal
represent
consist
data
obtain
statist
analysi
perform
use
student
unpair
test
data
present
mean
sem
p
p
p
human
studi
approv
ethic
committe
guangzhou
eighth
peopl
hospit
guangzhou
medic
univers
research
conduct
strict
accord
chines
govern
rule
regul
protect
human
subject
studi
subject
provid
written
inform
consent
research
use
blood
sampl
procedur
anim
undertaken
accord
experiment
anim
welfar
ethic
committe
tsinghua
univers
experi
perform
guidelin
experiment
anim
welfar
ethic
committe
tsinghua
univers
nextgener
sequenc
ng
power
tool
probe
antibodi
respons
natur
infect
vaccin
extens
studi
broadli
neutral
antibodi
bnab
lineag
develop
use
ng
reveal
unexpect
complex
divers
b
cell
repertoir
individu
chronic
infect
perform
longitudin
ng
analysi
antibodi
repertoir
delin
dynam
b
cell
respons
zikv
infect
follow
procedur
outlin
figur
analyz
seven
sequenti
time
point
acut
phase
day
day
onset
symptom
convalesc
phase
month
onset
symptom
combin
pcr
singl
revers
primer
templat
prepar
ensur
ng
longread
bp
unbias
manner
previous
report
figur
deep
sequenc
yield
total
million
heavi
chain
million
light
chain
two
separ
ng
run
ion
genestudio
platform
tabl
antibodyom
pipelin
use
process
annot
analyz
ng
data
render
million
read
per
time
point
tabl
sequenc
highqual
fulllength
antibodi
variabl
region
use
indepth
analysi
b
cell
repertoir
profil
tabl
furthermor
trace
lineag
within
ngsderiv
repertoir
synthes
repres
somat
variant
function
character
vitro
vivo
figur
overal
exhibit
divers
dynam
distribut
germlin
gene
usag
figur
germlin
gene
domin
seven
time
point
averag
greater
figur
left
contrast
specif
germlin
gene
observ
low
frequenc
vh
germlin
gene
rang
seven
time
point
figur
left
vl
germlin
gene
correspond
rang
figur
right
howev
low
frequenc
unexpect
suggest
repres
major
b
cell
lineag
repertoir
span
acut
convalesc
phase
zikv
infect
addit
appear
correl
potenc
zikv
etarget
mab
lineag
expans
preval
indic
low
frequenc
germlin
gene
famili
determin
degre
shm
germlin
diverg
time
point
earli
acut
phase
late
convalesc
phase
shown
figur
signific
increas
popul
germlinelik
sequenc
day
heavi
light
chain
result
averag
shm
heavi
chain
repertoir
fell
day
respect
note
shm
decreas
v
gene
famili
day
suggest
repertoirelevel
respons
figur
vh
germlin
gene
show
shm
day
vari
time
point
figur
left
vl
germlin
gene
display
shm
day
time
point
studi
figur
right
result
suggest
drastic
shift
repertoir
composit
like
caus
rapid
plasmablast
respons
acut
phase
zikv
infect
emerg
develop
may
serv
exampl
type
antibodi
respons
pattern
consist
fact
plasmablast
zikvinfect
individu
exhibit
less
somat
hypermut
clonal
expans
compar
zikvinfect
denvimmun
individu
may
origin
common
memori
b
cell
clone
interestingli
similar
pattern
also
report
chronic
infect
patient
respons
rapidli
evolv
viru
popul
next
determin
distribut
loop
length
due
divers
gene
rather
dispers
distribut
loop
length
observ
compar
steadi
canon
loop
length
distribut
obtain
chain
figur
loop
mainli
distribut
rang
figur
left
light
chain
loop
account
chain
repertoir
loop
account
chain
repertoir
figur
middl
right
result
case
studi
reveal
uniqu
featur
human
b
cell
repertoir
acut
transient
zikv
infect
futur
studi
longitudin
sampl
larger
cohort
infect
donor
would
need
valid
find
probe
matur
pathway
trace
mab
lineag
time
point
within
ngsderiv
repertoir
figur
b
ident
respect
wt
heavi
chain
use
cutoff
identifi
sequenc
evolutionarili
relat
figur
b
shown
magenta
dot
plot
report
previous
wt
deriv
memori
b
cell
month
symptom
onset
unexpectedli
librari
unbiasedli
amplifi
germlin
gene
famili
could
find
heavi
chain
somat
variant
repertoir
seven
time
point
suggest
lineag
may
extrem
low
frequenc
figur
upper
panel
gain
insight
lineag
evolut
perform
addit
ng
experi
four
antibodi
librari
day
month
use
degener
forward
primer
target
heavi
chain
put
germlin
gene
figur
lower
panel
genespecif
ng
yield
heavi
chain
day
two
month
figur
lower
panel
chain
repertoir
chain
somat
variant
detect
day
reach
peak
day
identifi
variant
persist
month
despit
notic
declin
month
figur
note
due
lack
gene
segment
light
chain
possess
unambigu
sequenc
signatur
lineag
trace
nonetheless
data
suggest
variant
induc
rapidli
transient
end
acut
phase
zikv
infect
interestingli
major
somat
variant
show
germlin
diverg
heavi
chain
repertoir
figur
low
panel
figur
studi
matur
pathway
select
repres
somat
variant
antibodi
synthesi
function
character
hierarch
cluster
method
use
sequenc
select
previous
describ
addit
domin
sequenc
consensu
select
conduct
base
sequenc
characterist
ensur
broad
coverag
repres
repres
heavi
chain
select
day
month
repres
chain
day
month
figur
somat
variant
design
base
order
select
eg
select
sequenc
repres
heavi
chain
somat
variant
surprisingli
ident
put
germlin
gene
correspond
ng
read
frequenc
high
respect
figur
furthermor
somat
variant
show
low
degre
shm
averag
ident
repres
heavi
chain
respect
put
germlin
gene
chain
averag
germlin
ident
also
high
figur
sequenc
align
variabl
region
repres
somat
variant
shown
figur
summar
antibodi
lineag
repres
transient
plasmablast
respons
low
degre
shm
end
acut
phase
zikv
infect
repres
somat
variant
synthes
pair
respect
wildtyp
wt
partner
chain
fulllength
human
express
function
character
synthes
heavi
chain
somat
variant
could
express
pair
wt
chain
figur
next
measur
bind
e
protein
e
diii
zikv
elisa
mong
mab
demonstr
strong
bind
affin
e
e
diii
similar
level
halfmaxim
effect
concentr
rang
ngml
remain
mab
show
low
affin
figur
zikv
e
protein
e
diii
express
bacteri
cell
follow
procedur
previous
describ
crystallograph
analysi
must
note
affin
mab
may
vari
depend
express
system
use
produc
antigen
nonetheless
affin
wt
ngml
compar
obtain
use
zikv
e
ngml
confirm
antigen
bind
somat
variant
mab
employ
plaqu
reduct
neutral
test
two
zikv
strain
asian
african
denv
figur
consist
bind
affin
strong
binder
neutral
potent
figur
halfmaxim
inhibitori
concentr
rang
ngml
compar
wt
potent
etarget
mab
isol
zikvinfect
human
subject
figur
surprisingli
fail
show
detect
potenc
ngml
exhibit
modest
neutral
activ
ngml
ngml
similarli
show
neglig
neutral
activ
two
zikv
strain
test
ngml
ngml
figur
mab
show
crossneutr
activ
denv
figur
strikingli
ident
show
high
affin
fulllength
e
e
diii
zikv
valu
measur
ngml
ngml
respect
figur
consist
also
display
potent
neutral
valu
ngml
ngml
respect
b
notabl
heavi
chain
day
ident
confirm
germlinelik
mab
lineag
emerg
peak
plasmablast
respons
base
align
germlin
sequenc
function
loss
could
potenti
explain
mutat
locat
toward
end
figur
synthes
chain
express
pair
wt
heavi
chain
note
chain
variant
fail
bind
zikv
e
e
diii
show
undetect
neutral
zikv
figur
among
chain
variant
sequenc
ident
repres
larg
portion
day
chain
figur
reconstitut
mab
contain
demonstr
rather
weak
bind
neutral
compar
wt
figur
function
repertoir
observ
togeth
sequenc
align
suggest
could
critic
matur
chain
figur
taken
togeth
result
function
character
heavi
chain
somat
variant
confirm
hypothesi
mab
lineag
repres
transient
yet
effect
b
cell
respons
zikv
infect
loss
function
observ
chain
somat
variant
vl
revert
suggest
light
chain
matur
crucial
lineag
acquir
potenc
specif
reminisc
bnab
previous
demonstr
protect
mice
lethal
zikv
infect
microcephali
conduct
similar
anim
studi
confirm
accuraci
repertoir
analysi
also
provid
use
clue
function
divers
lineag
vivo
end
test
vivo
protect
repres
somat
variant
zikv
lethal
infect
mice
mice
defici
receptor
follow
protocol
outlin
figur
briefli
administ
mab
posit
control
neg
control
group
four
mice
week
age
via
intraperiton
ip
rout
fig
follow
day
anim
challeng
plaqueform
unit
pfu
zikv
asian
strain
via
intraperiton
ip
rout
figur
anim
monitor
surviv
rate
day
zikv
challeng
viral
rna
level
blood
day
post
zikv
challeng
figur
expect
vivo
protect
mab
correl
vitro
neutral
previous
report
exampl
heavi
chain
variant
potent
neutral
activ
vitro
provid
complet
protect
surviv
rate
day
zikv
challeng
figur
rna
load
group
suppress
blood
distinguish
level
group
figur
convers
fail
offer
protect
median
surviv
time
day
zikv
challeng
figur
viral
rna
level
measur
mice
treat
variant
averag
greater
group
day
zikv
challeng
figur
contrast
chain
variant
demonstr
consist
surviv
rate
ident
neg
control
fail
suppress
viral
replic
figur
g
therefor
vivo
evalu
repres
somat
variant
confirm
differenti
effect
heavi
chain
antibodi
function
consist
vitro
character
elisa
neutral
assay
investig
matur
pathway
lineag
perform
revers
mutagenesi
structur
analysi
identifi
hotspot
residu
initi
align
amino
acid
sequenc
repres
heavi
chain
variant
put
germlin
gene
respect
figur
heavi
chain
variant
lost
potenc
zikv
vitro
vivo
heavi
chain
possess
singl
substitut
mutat
residu
respect
germlin
gene
figur
assess
whether
caus
reduc
potenc
conduct
revers
mutagenesi
character
function
mutant
elisa
neutral
assay
shown
figur
mutant
regain
zikv
ebind
neutral
activ
approach
level
wt
due
use
differ
vh
germlin
gene
mutant
ineffect
figur
result
suggest
lineag
restrict
vh
gene
usag
achiev
high
affin
potenc
zikv
base
crystal
structur
complex
zikv
e
diii
four
residu
within
loop
directli
involv
contact
interfac
although
within
loop
form
hydrogen
bond
opposit
side
loop
thu
stabil
conform
figur
result
provid
evid
lineag
inde
gener
b
cell
respons
acut
zikv
infect
critic
residu
encod
germlin
gene
chain
variant
two
critic
mutat
identifi
potenti
contribut
matur
lineag
figur
one
mutat
locat
loop
share
two
weakli
function
variant
well
wt
chain
figur
mutat
posit
loop
wt
chain
predominantli
weakli
nonfunct
chain
variant
figur
thu
could
potenti
critic
mutat
chain
matur
first
examin
effect
two
mutat
individu
perform
sitedirect
mutagenesi
ident
germlin
gene
neither
could
render
germlin
antibodi
function
figur
introduc
doubl
mutat
expect
bound
zikv
e
e
diii
high
affin
potent
neutral
zikv
level
wt
figur
shown
crystal
structur
five
residu
within
chain
directli
involv
contact
interfac
two
ngsidentifi
hotspot
residu
directli
interact
zikv
e
diii
form
hydrogen
bond
interact
zikv
e
diii
figur
brief
combin
analysi
ng
data
antibodi
function
complex
structur
confirm
residu
within
chain
essenti
thu
repres
crucial
event
necessari
function
matur
zikv
e
diiidirect
antibodi
lineag
studi
delin
b
cell
repertoir
respons
zikvinfect
individu
natur
infect
use
ngsbase
approach
futur
studi
sequenti
sampl
patient
would
need
valid
support
current
find
analysi
show
antibodi
repertoir
profil
divers
germlin
usag
limit
somat
hypermut
variabl
gene
steadi
loop
length
trace
ngsderiv
antibodi
repertoir
reveal
dynam
effect
germlineencod
antibodi
lineag
emerg
prior
convalesc
phase
zikv
infect
germlinelik
somat
variant
deriv
lineag
potent
neutral
zikv
protect
mice
lethal
zikv
challeng
show
crossreact
denv
also
demonstr
two
mutat
within
germlineencod
chain
essenti
function
matur
antibodi
lineag
two
import
aspect
studi
worth
highlight
one
effect
germlineencod
antibodi
respons
repres
lineag
observ
signific
increas
germlinelik
antibodi
day
onset
symptom
drastic
shift
repertoir
composit
like
result
rapid
plasmablast
respons
toward
end
acut
phase
zikv
infect
interestingli
shift
coincid
emerg
lineag
exemplifi
role
germlineencod
antibodi
respons
zikv
infect
similar
pattern
describ
previou
studi
monoclon
antibodi
germlinelik
human
mab
report
target
zikv
e
diii
cryptic
epitop
cc
loop
neutral
zikv
potent
vitro
vivo
anoth
human
mab
origin
germlin
gene
ident
neutral
zikv
potent
well
overal
b
cell
respons
plasmablastderiv
antibodi
zikvinfect
donor
show
low
level
shm
support
mechan
b
cell
activ
low
level
igg
shm
also
report
acut
denv
infect
consist
innatelik
antivir
recognit
mediat
b
cell
possess
antigenspecif
b
cell
receptor
therefor
induct
germlineencod
neutral
antibodi
critic
effect
protect
acut
flaviviru
infect
divers
mechan
antibodi
lineag
develop
found
chronic
infect
infect
rapidli
emerg
mperdirect
antibodi
lineag
report
achiev
neutral
breadth
low
level
shm
contrast
bnab
target
bind
site
stem
respect
requir
extens
mutat
achiev
neutral
breadth
potenc
addit
long
loop
requir
bnab
penetr
glycan
shield
envelop
spike
summari
longitudin
analysi
repertoir
lineag
develop
provid
insight
possibl
protect
immun
zikv
infect
must
note
zikvinfect
donor
need
analyz
futur
studi
confirm
bcell
repertoir
dynam
respons
zikv
infect
observ
howev
longitudin
patient
sampl
cover
entir
cours
infect
usual
scarc
due
difficulti
earli
diagnosi
sampl
collect
pose
signific
challeng
studi
import
aspect
studi
implic
ration
design
safe
effect
zikv
vaccin
previous
report
e
diiispecif
mab
zikvspecif
potent
neutral
protect
mice
lethal
zikv
challeng
structur
studi
reveal
bind
residu
within
later
ridg
diii
block
infect
postattach
step
similar
e
diiispecif
potent
neutral
mab
addit
e
diiispecif
antibodi
critic
control
zikv
correl
posit
high
neutral
titer
deplet
result
reduc
neutral
activ
zikvinfect
patient
serum
result
indic
two
mutat
germlin
chain
suffici
enabl
germlin
antibodi
achiev
potent
zikv
neutral
therefor
barrier
could
readili
overcom
antigenactiv
b
cell
repertoir
low
degre
shm
observ
lineag
suggest
elicit
protect
b
cell
respons
zikv
may
achiev
standard
vaccin
regimen
furthermor
e
diiibas
vaccin
report
avert
lethal
west
nile
viru
wnv
infect
without
enhanc
zikv
denv
infect
howev
low
frequenc
transient
expans
antibodi
observ
repertoir
suggest
overcom
suboptim
immunogen
zikv
e
diii
elong
immunoglobulinlik
domain
may
prove
signific
challeng
zikv
vaccin
develop
mani
e
diiidirect
antibodi
potent
neutral
antibodi
target
quaternari
epitop
also
report
except
neutral
potenc
longitudin
analysi
quaternari
antibodi
provid
valuabl
insight
protect
immun
zikv
infect
inform
ration
vaccin
design
warrant
investig
dataset
analyz
manuscript
publicli
avail
request
access
dataset
direct
jiang
scrippsedu
studi
involv
human
particip
review
approv
ethic
committe
guangzhou
eighth
peopl
hospit
guangzhou
medic
univers
patientsparticip
provid
written
inform
consent
particip
studi
anim
studi
review
approv
experiment
anim
welfar
ethic
committe
tsinghua
univers
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
